828 Shares in Amgen Inc. (NASDAQ:AMGN) Bought by Fielder Capital Group LLC

Key Points

• Fielder Capital Group LLC acquired 828 shares of Amgen Inc., valued at approximately $258,000, marking a new investment position in the company during the first quarter.
• Several institutional investors, including First Pacific Financial and Global Wealth Strategies & Associates, significantly increased their stakes in Amgen, leading to 76.50% of the stock currently owned by institutional investors.
• Amgen reported strong earnings, beating analysts' expectations with $4.90 earnings per share for the last quarter, a year-over-year revenue increase of 9.4% to $8.15 billion.

Fielder Capital Group LLC acquired a new position in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 828 shares of the medical research company's stock, valued at approximately $258,000.

Several other institutional investors and hedge funds have also modified their holdings of AMGN. First Pacific Financial boosted its stake in shares of Amgen by 304.5% during the first quarter. First Pacific Financial now owns 89 shares of the medical research company's stock valued at $28,000 after purchasing an additional 67 shares in the last quarter. Pinney & Scofield Inc. acquired a new stake in shares of Amgen during the fourth quarter valued at about $26,000. Ritter Daniher Financial Advisory LLC DE boosted its stake in shares of Amgen by 66.2% during the fourth quarter. Ritter Daniher Financial Advisory LLC DE now owns 128 shares of the medical research company's stock valued at $33,000 after purchasing an additional 51 shares in the last quarter. Global Wealth Strategies & Associates boosted its stake in shares of Amgen by 1,388.9% during the first quarter. Global Wealth Strategies & Associates now owns 134 shares of the medical research company's stock valued at $42,000 after purchasing an additional 125 shares in the last quarter. Finally, Heck Capital Advisors LLC acquired a new stake in shares of Amgen during the fourth quarter valued at about $36,000. 76.50% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

AMGN has been the topic of a number of recent research reports. William Blair reissued an "outperform" rating on shares of Amgen in a research note on Tuesday, June 24th. Royal Bank Of Canada decreased their price target on Amgen from $324.00 to $320.00 and set an "outperform" rating for the company in a research note on Friday, May 2nd. UBS Group increased their price target on Amgen from $315.00 to $326.00 and gave the company a "neutral" rating in a research note on Monday, July 21st. Wall Street Zen raised Amgen from a "buy" rating to a "strong-buy" rating in a research note on Sunday, May 18th. Finally, Cantor Fitzgerald reissued a "neutral" rating and issued a $305.00 price target on shares of Amgen in a research note on Tuesday, June 24th. Two investment analysts have rated the stock with a sell rating, twelve have issued a hold rating, eight have assigned a buy rating and two have issued a strong buy rating to the company's stock. Based on data from MarketBeat, Amgen has an average rating of "Hold" and a consensus price target of $307.27.

Insider Buying and Selling at Amgen

In other news, SVP Rachna Khosla sold 1,500 shares of the firm's stock in a transaction that occurred on Thursday, June 5th. The stock was sold at an average price of $289.68, for a total value of $434,520.00. Following the transaction, the senior vice president owned 8,162 shares in the company, valued at $2,364,368.16. This trade represents a 15.52% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 0.76% of the stock is owned by corporate insiders.

Amgen Trading Down 0.6%

Shares of Amgen stock opened at $306.58 on Monday. The company has a debt-to-equity ratio of 8.70, a quick ratio of 0.88 and a current ratio of 1.17. Amgen Inc. has a 52 week low of $253.30 and a 52 week high of $340.89. The stock has a 50 day moving average price of $289.39 and a two-hundred day moving average price of $291.07. The stock has a market capitalization of $164.85 billion, a PE ratio of 27.97, a price-to-earnings-growth ratio of 2.65 and a beta of 0.49.

Amgen (NASDAQ:AMGN - Get Free Report) last posted its earnings results on Thursday, May 1st. The medical research company reported $4.90 earnings per share for the quarter, beating analysts' consensus estimates of $4.18 by $0.72. Amgen had a return on equity of 176.11% and a net margin of 17.39%. The company had revenue of $8.15 billion for the quarter, compared to analyst estimates of $8.05 billion. During the same quarter last year, the company earned $3.96 earnings per share. The company's revenue for the quarter was up 9.4% on a year-over-year basis. As a group, equities analysts anticipate that Amgen Inc. will post 20.62 earnings per share for the current fiscal year.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.